COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,788 Articles (22,523 medRxiv, 8,265 bioRxiv)

Most recent first Previous |  Page 1481: Articles 14801-14810  | Next

Pan-ErbB inhibition protects from SARS-CoV-2 replication, inflammation, and injury
Saul, S., Karim, M., Huang, P. T., Ghita, L., Chiu, W., Kumar, S., Bhalla, N., Leyssen, P., Cohen, C. A., Huie, K. E., Tindle, C., Sahoo, M. K., Sibai, M., Pinsky, B. A., Das, S., Ghosh, P., Dye, J., Solow-Cordero, D. E., Jin, J., Jochmans, D., Neyts, J., Narayanan, A., De Jonghe, S., Einav, S.
10.1101/2021.05.15.444128 — Posted: 2021-05-16
Stabilization of the SARS-CoV-2 Spike receptor-binding domain using deep mutational scanning and structure-based design
Ellis, D., Brunette, N., Crawford, K. H. D., Walls, A. C., Pham, M. N., Chen, C., Herpoldt, K.-L., Fiala, B., Murphy, M., Pettie, D., Kraft, J. C., Malone, K. D., Navarro, M. J., Ogohara, C., Kepl, E., Ravichandran, R., Sydeman, C., Ahlrichs, M., Johnson, M., Blackstone, A., Carter, L., Starr, T. N., Greaney, A. J., Lee, K. K., Veesler, D., Bloom, J. D., King, N. P.
10.1101/2021.05.15.444222 — Posted: 2021-05-16
Allicin inhibits SARS-CoV-2 replication and abrogates the antiviral host response in the Calu-3 proteome
Mösbauer, K., Fritsch, V. N., Adrian, L., Bernhardt, J., Gruhlke, M. C. H., Slusarenko, A. J., Niemeyer, D., Antelmann, H.
10.1101/2021.05.15.444275 — Posted: 2021-05-16
The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccine-elicited and Therapeutic Monoclonal Antibodies.
Tada, T., Zhou, H., Dcosta, B. M., Samanovic, M. I., Mulligan, M. J., Landau, N. R.
10.1101/2021.05.14.444076 — Posted: 2021-05-16
Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants
Pegu, A., O'Connell, S. E., Schmidt, S. D., O'Dell, S., Talana, C. A., Lai, L., Albert, J., Anderson, E., Bennett, H., Corbett, K., Flach, B., Jackson, L., Leav, B., Ledgerwood, J. E., Luke, C. J., Makowski, M., Roberts, P. C., Roederer, M., Rebolledo, P. A., Rostad, C. A., Rouphael, N. G., Shi, W., Wang, L., Widge, A. T., Yang, E. S., Beigel, J. H., Graham, B. S., Mascola, J. R., Suthar, M. S., McDermott, A., Doria-Rose, N. A.
10.1101/2021.05.13.444010 — Posted: 2021-05-16
Potent neutralization of SARS-CoV-2 variants of concern by an antibody with a unique genetic signature and structural mode of spike recognition
Kramer, K. J., Johnson, N. V., Shiakolas, A. R., Suryadevara, N., Periasamy, S., Raju, N., Williams, J. K., Wrapp, D., Zost, S. J., Holt, C. M., Hsieh, C.-L., Sutton, R. E., Paulo, A., Davidson, E., Doranz, B. J., Crowe, J. E., Bukreyev, A., Carnahan, R. H., McLellan, J. S., Georgiev, I. S.
10.1101/2021.05.16.444004 — Posted: 2021-05-16
CovidExpress: an interactive portal for intuitive investigation on SARS-CoV-2 related transcriptomes
Djekidel, M. N., Rosikiewicz, W., Peng, J. C., Kanneganti, T.-D., Hui, Y., Jin, H., Hedges, D., Schreiner, P., Fan, Y., Wu, G., Xu, B.
10.1101/2021.05.14.444026 — Posted: 2021-05-16
Evaluation of SARS-CoV-2 rapid antigen diagnostic tests for saliva samples
Hagbom, M., Carmona-Vicente, N., Sharma, S., Olsson, H., Jamtberg, M., Nilsdotter-Augustinsson, A., Sjowall, J., Nordgren, J.
10.1101/2021.05.14.21257100 — Posted: 2021-05-16
Toxoplasmosis: An important risk factor for acquiring SARS-CoV-2 infection and a severe course of Covid-19 disease
Flegr, J.
10.1101/2021.05.15.21257257 — Posted: 2021-05-16 Discussion: Onsite
Hydroxychloroquine For Prophylaxis Of COVID-19 In Health Workers: A Randomized Clinical Trial.
Rojas-Serrano, J., Portillo-Vasquez, A. M., Thirion-Romero, I., Vazquez-Perez, J., Mejia-Nepomuceno, F., Ramirez-Venegas, A., Perez-Kawabe, K. M., Perez-Padilla, R., RESEARCH GROUP ON HYDROXYCHLOROQUINE FOR COVID-19
10.1101/2021.05.14.21257059 — Posted: 2021-05-16

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).